GlassScriptPhysician profile
Joel A Ernster
NPI 1023017845
$750.27
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $338 · 2021: $113 · 2022: $57.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $193.91 | 2019-2021 | |
| Stryker Corporation | $173.47 | 2019-2021 | |
| Agiliti Surgical, INC. | $73.41 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.11 | 2019-2022 | |
| Optinose US, INC. | $54.44 | 2019-2020 | |
| Intersect Ent, INC. | $49.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $41.52 | 2019-2022 | |
| Genzyme Corporation | $32.86 | 2019-2021 | |
| Medtronic, INC. | $31.88 | 2021 | |
| Aerin Medical INC. | $22.34 | 2022 | |
| Shire North American Group INC | $16.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Ernster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.